No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CERE240621C40000
- 1.50
- +0.78+108.33%
15min DelayClose Jun 12 15:59 ET
1.50High0.78Low
0.78Open0.72Pre Close51 Volume596 Open Interest40.00Strike Price7.48KTurnover38.85%IV1.10%PremiumJun 21, 2024Expiry Date1.05Intrinsic Value100Multiplier8DDays to Expiry0.45Extrinsic Value100Contract SizeAmericanOptions Type0.6842Delta0.1432Gamma25.26Leverage Ratio-0.0549Theta0.0064Rho17.28Eff Leverage0.0227Vega
Intraday
- 5D
- 1D
News
Cerevel Therapeutics Gains After AbbVie Says Making Good Progress With FTC
Catalyst Watch: Apple's WWDC, Tesla's Annual Meeting, Fed's Dot Plot, and GameStop Volatility
Unusual Options Activity: TMUS, CERE and Others Attract Market Bets, TMUS V/OI Ratio Reaches 161.3
EST Jun 6th Afternoon Delivery - In the last two hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Cerevel Therapeutics Holdings(CERE.US) Director Sells US$2.03 Million in Common Stock
$Cerevel Therapeutics Holdings(CERE.US)$ Director COLES N ANTHONY sold 50,000 shares of common stock on Jun 3, 2024 at an average price of $40.6104 for a total value of $2.03 million.Source: Announcem
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Form 144 | Cerevel Therapeutics Holdings(CERE.US) Director Proposes to Sell 2.04 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 3, $Cerevel Therapeutics Holdings(CERE.US)$ Director NEAVELLE ANTHONY COLES intends to sell 50,000 shares of its common stock on Jun 3, with a total market value of approxi
Comments
» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
7
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
6
Ticker Report
$WIMI Evaluate Research reiterated a "buy" rating with $7 latest price target for WIMI Hologram Cloud(NASDAQ: WIMI)
$PACB Barclays Trims Pacific Biosciences of California (NASDAQ:PACB) Target Price to $3.00
$NFLX Netflix, Inc. (NASDAQ:NFLX) Receives $590.15 Consensus Target Price from Brokerages
$SNOW Brokerages Set Snowflake Inc. (NYSE:SNOW) Target Price at $202.50
$RCI Barclays Trims Rogers Communications (NYSE:RCI) Target Price to $46.00
$CERE Cerevel Thera...
$WIMI Evaluate Research reiterated a "buy" rating with $7 latest price target for WIMI Hologram Cloud(NASDAQ: WIMI)
$PACB Barclays Trims Pacific Biosciences of California (NASDAQ:PACB) Target Price to $3.00
$NFLX Netflix, Inc. (NASDAQ:NFLX) Receives $590.15 Consensus Target Price from Brokerages
$SNOW Brokerages Set Snowflake Inc. (NYSE:SNOW) Target Price at $202.50
$RCI Barclays Trims Rogers Communications (NYSE:RCI) Target Price to $46.00
$CERE Cerevel Thera...
Analysts believe AbbVie's early acquisition of Cerevel, despite high risks, could potentially yield high returns and avoid bidding wars if emraclidine's data is positive. It's also seen as a strategic move to enhance AbbVie's long-term pipelines.
Analyst Mohit Bansal opines AbbVie might favour purchasing Cerevel due to its perceived clean IP and daily dosing for its principal schizophrenia medication. He anticipates potential benefit from peak adjustments in sales surpassing $3B.
1
Read more